ResearchMoz

Type 2 Diabetes - Pipeline Review, H1 2014

Global Markets Direct
Published Date » 2014-02-28
No. Of Pages » 1052
 Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2014’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline. 
   
 This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. 
   
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000...
Table of Content

Introduction
Type 2 Diabetes Overview
Therapeutics Development
Type 2 Diabetes - Therapeutics under Development by Companies
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
Type 2 Diabetes - Pipeline Products Glance
Type 2 Diabetes - Products under Development by Companies
Type 2 Diabetes - Products under Investigation by Universities/Institutes
Type 2 Diabetes - Companies Involved in Therapeutics Development
Type 2 Diabetes - Therapeutics Assessment
Drug Profiles
Type 2 Diabetes - Recent Pipeline Updates
Type 2 Diabetes - Dormant Projects
Type 2 Diabetes - Discontinued Products
Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)
Number of Products under Development by Companies, H1 2014 (Contd..8)
Number of Products under Development by Companies, H1 2014 (Contd..9)
Number of Products under Development by Companies, H1 2014 (Contd..10)
Number of Products under Development by Companies, H1 2014 (Contd..11)
Number of Products under Development by Companies, H1 2014 (Contd..12)
Number of Products under Development by Companies, H1 2014 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Development by Companies, H1 2014 (Contd..4)
Products under Development by Companies, H1 2014 (Contd..5)
Products under Development by Companies, H1 2014 (Contd..6)
Products under Development by Companies, H1 2014 (Contd..7)
Products under Development by Companies, H1 2014 (Contd..8)
Products under Development by Companies, H1 2014 (Contd..9)
Products under Development by Companies, H1 2014 (Contd..10)
Products under Development by Companies, H1 2014 (Contd..11)
Products under Development by Companies, H1 2014 (Contd..12)
Products under Development by Companies, H1 2014 (Contd..13)
Products under Development by Companies, H1 2014 (Contd..14)
Products under Development by Companies, H1 2014 (Contd..15)
Products under Development by Companies, H1 2014 (Contd..16)
Products under Development by Companies, H1 2014 (Contd..17)
Products under Development by Companies, H1 2014 (Contd..18)
Products under Development by Companies, H1 2014 (Contd..19)
Products under Development by Companies, H1 2014 (Contd..20)
Products under Development by Companies, H1 2014 (Contd..21)
Products under Development by Companies, H1 2014 (Contd..22)
Products under Development by Companies, H1 2014 (Contd..23)
Products under Development by Companies, H1 2014 (Contd..24)
Products under Development by Companies, H1 2014 (Contd..25)
Products under Development by Companies, H1 2014 (Contd..26)
Products under Development by Companies, H1 2014 (Contd..27)
Products under Investigation by Universities/Institutes, H1 2014
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2014
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2014
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2014
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanofi, H1 2014
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2014
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2014
Type 2 Diabetes - Pipeline by GlaxoSmithKline plc, H1 2014
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2014
Type 2 Diabetes - Pipeline by Isis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2014
Type 2 Diabetes - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2014
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2014
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2014
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Type 2 Diabetes - Pipeline by FibroGen, Inc., H1 2014
Type 2 Diabetes - Pipeline by Ipsen S.A., H1 2014
Type 2 Diabetes - Pipeline by Piramal Enterprises Limited, H1 2014
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2014
Type 2 Diabetes - Pipeline by Novartis AG, H1 2014
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2014
Type 2 Diabetes - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Forest Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2014
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Les Laboratoires Servier SAS, H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2014
Type 2 Diabetes - Pipeline by Ranbaxy Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2014
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2014
Type 2 Diabetes - Pipeline by Bayer AG, H1 2014
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2014
Type 2 Diabetes - Pipeline by MannKind Corporation, H1 2014
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2014
Type 2 Diabetes - Pipeline by Merck KGaA, H1 2014
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2014
Type 2 Diabetes - Pipeline by Addex Therapeutics, H1 2014
Type 2 Diabetes - Pipeline by Evotec AG, H1 2014
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2014
Type 2 Diabetes - Pipeline by GW Pharmaceuticals plc, H1 2014
Type 2 Diabetes - Pipeline by Harbor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2014
Type 2 Diabetes - Pipeline by Genfit SA, H1 2014
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2014
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014
Type 2 Diabetes - Pipeline by ConjuChem Biotechnologies Inc., H1 2014
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2014
Type 2 Diabetes - Pipeline by CSL Limited, H1 2014
Type 2 Diabetes - Pipeline by ProteoTech, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2014
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2014
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2014
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Xenetic Biosciences plc, H1 2014
Type 2 Diabetes - Pipeline by Handok Inc., H1 2014
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by LG Life Sciences, Ltd., H1 2014
Type 2 Diabetes - Pipeline by Transition Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2014
Type 2 Diabetes - Pipeline by Summit Corporation plc, H1 2014
Type 2 Diabetes - Pipeline by Phynova Group Ltd, H1 2014
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2014
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2014
Type 2 Diabetes - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
Type 2 Diabetes - Pipeline by Angelini Group, H1 2014
Type 2 Diabetes - Pipeline by Debiopharm International S.A., H1 2014
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2014
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2014
Type 2 Diabetes - Pipeline by Aurigene Discovery Technologies Limited, H1 2014
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2014
Type 2 Diabetes - Pipeline by Camurus AB, H1 2014
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by reMYND, H1 2014
Type 2 Diabetes - Pipeline by Wellstat Therapeutics Corporation, H1 2014
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2014
Type 2 Diabetes - Pipeline by Cortendo Invest AB, H1 2014
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Protemix Corporation Limited, H1 2014
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2014
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Co., H1 2014
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Melior Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by Diabetology Limited, H1 2014
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2014
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2014
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2014
Type 2 Diabetes - Pipeline by Versartis, Inc., H1 2014
Type 2 Diabetes - Pipeline by Kainos Medicine, Inc., H1 2014
Type 2 Diabetes - Pipeline by Nordic Bioscience a/s, H1 2014
Type 2 Diabetes - Pipeline by InteKrin Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2014
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2014
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2014
Type 2 Diabetes - Pipeline by TransTech Pharma, Inc., H1 2014
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2014
Type 2 Diabetes - Pipeline by Synthetic Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Targacept, Inc., H1 2014
Type 2 Diabetes - Pipeline by N-Gene Research Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2014
Type 2 Diabetes - Pipeline by USV Limited, H1 2014
Type 2 Diabetes - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2014
Type 2 Diabetes - Pipeline by Verva Pharmaceuticals Limited, H1 2014
Type 2 Diabetes - Pipeline by Exsulin Corporation, H1 2014
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2014
Type 2 Diabetes - Pipeline by NasVax Ltd., H1 2014
Type 2 Diabetes - Pipeline by Stelic Institute & Co., H1 2014
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2014
Type 2 Diabetes - Pipeline by Regulus Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2014
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014
Type 2 Diabetes - Pipeline by Receptos, Inc., H1 2014
Type 2 Diabetes - Pipeline by MicroDose Therapeutx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2014
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2014
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2014
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2014
Type 2 Diabetes - Pipeline by Stempeutics Research Private Limited, H1 2014
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2014
Type 2 Diabetes - Pipeline by SignPath Pharma Inc, H1 2014
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Thermalin Diabetes Inc., H1 2014
Type 2 Diabetes - Pipeline by Selvita S.A, H1 2014
Type 2 Diabetes - Pipeline by Poxel SA, H1 2014
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2014
Type 2 Diabetes - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Neopharm Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Metabolys S.A.S., H1 2014
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2014
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Allinky Biopharma, H1 2014
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals SA, H1 2014
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2014
Type 2 Diabetes - Pipeline by Curaxys, S.L., H1 2014
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2014
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Biospherics.net Incorporated, H1 2014
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2014
Type 2 Diabetes - Dormant Projects, H1 2014
Type 2 Diabetes - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Upcoming Reports:

Calcium Nitrate Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Calcium nitrate, a crystalline, odorless salt, has high moisture absorption and is commonly found as tetrahydrate. Calcium nitrate is produced by reaction of calcium carbonate and nitric acid lime stone is the commonly used source of carbonate. The compound is also produced as a byproduct during the production of calcium phosphate. Ammonium nitrate and calcium hydroxide are among other chemicals employed in the production of calcium nitrate. Calcium nitrate is a compound of calcium and nitrogen, two of the foremost nutrients required for plant growth owing to which, calcium nitrate...
Gas Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Some of the major factors driving the growth of gas market are growing populations, increasing urbanization, rapidly growing automobile sector, increasing need for power generation, and growth in petrochemical industry. For decades, gas has been delivered to businesses and homes throughout the world and it has become the most dependable energy source.  Some of the major challenges faced by developing countries are dependence on foreign countries, increasing CO2 emissions, and increase in renewable energy mandates. With increasing demands from growing population, and other...
Mental Disorders Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
A mental disorder is a psychological anomaly that is reflected in the behavior of the patient through distress, disability or any conduct that is not a part of a person’s normal mental development. The causes of mental disorders are varied in nature and many are also unclear. Psychiatric medication and psychotherapy are the two modes of treatment for mental disorder. In psychiatric medication drug classes such as antidepressants, anxiolytics, and antipsychotics are most commonly used.  Improvement in patient security policy, growth in domestic and foreign investment...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...